FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557733183> ?p ?o ?g. }

• W2557733183 abstract "Abstract Multiple myeloma (MM) is a bone marrow-based malignancy characterized by expansion of plasma cells that produce monoclonal immunoglobulin. Although many new options are available to treat MM, patients develop resistance to these agents. Thus, new therapeutic options are necessary for patients. Vincristine has been used to treat MM but its neurotoxic side effects and low level of anti-MM activity have limited its clinical use. Pharmacokinetic studies on a different formulation of this vinca alkaloid, vincristine sulfate liposomes injection (VSLI, Marqibo®), have shown that the altered distribution and elimination phases with this drug may lead to increased exposure within the tumor versus traditional vincristine. Thus, this new agent offers the potential to both reduce the neurotoxicity and increase the anti-MM effects compared to standard vincristine. In the present study, we evaluated the anti-MM effects of Marqibo and vincristine using two severe combined immunodeficiency (SCID) murine models of human MM. These models were developed from intramuscular (i.m.) implantation of bone marrow biopsies from a MM patient before (LAGκ-1A) and following (LAGκ-1B) the development of both melphalan and bortezomib resistance clinically and have been successfully passaged. One week following implantation i.m., mice were treated with Marqibo, vincristine or vehicle alone. Marqibo was administered intravenously (i.v.) once weekly for three weeks at 0.5, 1, and 2.5 mg/kg and vincristine was given three times per week (M, W, F) i.v. at 0.3 mg/kg. Mice were bled in order to obtain sera to measure human immunoglobulin (Ig) G levels and tumor volume measured weekly. hIgG levels were measured by ELISA and tumor volume using standard calipers. Treatment of LAGk-1A–bearing mice with Marqibo at 0.5, 1 and 2.5 mg/kg inhibited paraprotein secretion as determined by hIgG levels (P = 0.0001; P = 0.0002; P = 0.0055, respectively) compared to mice receiving vehicle. A reduction in tumor volume, compared to control mice, was also observed in mice treated with Marqibo at the specified doses (P = 0.0001; P = 0.0001; P = 0.0001, respectively) and also when compared to vincristine (P = 0.0006; P = 0.0003; P = 0.0001, respectively). In fact, mice treated with vincristine showed no reduction in tumor volume compared to vehicle alone-treated mice. Marqibo at 0.5 mg/kg contained almost half the quantity of free vincristine compared to vincristine administered at 0.3 mg/kg, yet a significant inhibition of both human paraprotein secretion and reduction of tumor volume was observed in LAGκ-1A-bearing mice treated with this dose of Marqibo. The vincristine dose was administered three times more often than Marqibo, contained almost 100% more free vincristine compared to Marqibo at 0.5 mg/kg and most importantly was less effective. Mice bearing a slower growing MM tumor, LAGκ-1B, have recently begun treatment using the same doses and schedules as the LAGκ-1A study. This study is currently ongoing but preliminary data show inhibition of tumor volume growth and inhibition of IgG levels using Marqibo at 0.5, 1 and 2.5 mg/kg (hIgG; P = 0.011, P = 0.0045 and P = 0.0060, respectively). The results of this study show that Marqibo, a novel liposomal formulation of vincristine, produces anti-MM effects in this SCID-hu model of human MM whereas vincristine showed no anti-MM tumor volume growth activity. Further studies are currently being conducted to explore the optimal schedule and effects of this new agent in combination with other active MM agents. These studies should provide the rationale for further clinical development of Marqibo for the treatment of MM patients." @default.
• W2557733183 created "2016-12-08" @default.
• W2557733183 creator A5030964205 @default.
• W2557733183 creator A5038431825 @default.
• W2557733183 creator A5040835019 @default.
• W2557733183 creator A5050620647 @default.
• W2557733183 creator A5055490703 @default.
• W2557733183 creator A5061288330 @default.
• W2557733183 creator A5062550582 @default.
• W2557733183 creator A5090300095 @default.
• W2557733183 date "2008-11-16" @default.
• W2557733183 modified "2023-09-27" @default.
• W2557733183 title "In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma" @default.
• W2557733183 doi "https://doi.org/10.1182/blood.v112.11.2760.2760" @default.
• W2557733183 hasPublicationYear "2008" @default.
• W2557733183 type Work @default.
• W2557733183 sameAs 2557733183 @default.
• W2557733183 citedByCount "0" @default.
• W2557733183 crossrefType "journal-article" @default.
• W2557733183 hasAuthorship W2557733183A5030964205 @default.
• W2557733183 hasAuthorship W2557733183A5038431825 @default.
• W2557733183 hasAuthorship W2557733183A5040835019 @default.
• W2557733183 hasAuthorship W2557733183A5050620647 @default.
• W2557733183 hasAuthorship W2557733183A5055490703 @default.
• W2557733183 hasAuthorship W2557733183A5061288330 @default.
• W2557733183 hasAuthorship W2557733183A5062550582 @default.
• W2557733183 hasAuthorship W2557733183A5090300095 @default.
• W2557733183 hasConcept C112705442 @default.
• W2557733183 hasConcept C126322002 @default.
• W2557733183 hasConcept C150903083 @default.
• W2557733183 hasConcept C207001950 @default.
• W2557733183 hasConcept C2776364478 @default.
• W2557733183 hasConcept C2776553716 @default.
• W2557733183 hasConcept C2776694085 @default.
• W2557733183 hasConcept C2776755627 @default.
• W2557733183 hasConcept C2777096885 @default.
• W2557733183 hasConcept C2777478702 @default.
• W2557733183 hasConcept C2778684742 @default.
• W2557733183 hasConcept C2779429289 @default.
• W2557733183 hasConcept C2780007613 @default.
• W2557733183 hasConcept C71924100 @default.
• W2557733183 hasConcept C86803240 @default.
• W2557733183 hasConcept C98274493 @default.
• W2557733183 hasConceptScore W2557733183C112705442 @default.
• W2557733183 hasConceptScore W2557733183C126322002 @default.
• W2557733183 hasConceptScore W2557733183C150903083 @default.
• W2557733183 hasConceptScore W2557733183C207001950 @default.
• W2557733183 hasConceptScore W2557733183C2776364478 @default.
• W2557733183 hasConceptScore W2557733183C2776553716 @default.
• W2557733183 hasConceptScore W2557733183C2776694085 @default.
• W2557733183 hasConceptScore W2557733183C2776755627 @default.
• W2557733183 hasConceptScore W2557733183C2777096885 @default.
• W2557733183 hasConceptScore W2557733183C2777478702 @default.
• W2557733183 hasConceptScore W2557733183C2778684742 @default.
• W2557733183 hasConceptScore W2557733183C2779429289 @default.
• W2557733183 hasConceptScore W2557733183C2780007613 @default.
• W2557733183 hasConceptScore W2557733183C71924100 @default.
• W2557733183 hasConceptScore W2557733183C86803240 @default.
• W2557733183 hasConceptScore W2557733183C98274493 @default.
• W2557733183 hasLocation W25577331831 @default.
• W2557733183 hasOpenAccess W2557733183 @default.
• W2557733183 hasPrimaryLocation W25577331831 @default.
• W2557733183 hasRelatedWork W1443108546 @default.
• W2557733183 hasRelatedWork W1669741196 @default.
• W2557733183 hasRelatedWork W1996198321 @default.
• W2557733183 hasRelatedWork W2359170993 @default.
• W2557733183 hasRelatedWork W2369764254 @default.
• W2557733183 hasRelatedWork W2378628095 @default.
• W2557733183 hasRelatedWork W2380703843 @default.
• W2557733183 hasRelatedWork W2380807696 @default.
• W2557733183 hasRelatedWork W2387930885 @default.
• W2557733183 hasRelatedWork W2388762021 @default.
• W2557733183 hasRelatedWork W2398845841 @default.
• W2557733183 hasRelatedWork W2412227089 @default.
• W2557733183 hasRelatedWork W2413626457 @default.
• W2557733183 hasRelatedWork W2419265082 @default.
• W2557733183 hasRelatedWork W2545657964 @default.
• W2557733183 hasRelatedWork W2572796572 @default.
• W2557733183 hasRelatedWork W2582838532 @default.
• W2557733183 hasRelatedWork W2588538618 @default.
• W2557733183 hasRelatedWork W2588974447 @default.
• W2557733183 hasRelatedWork W2978553166 @default.
• W2557733183 isParatext "false" @default.
• W2557733183 isRetracted "false" @default.
• W2557733183 magId "2557733183" @default.
• W2557733183 workType "article" @default.